Free Trial!
Today’s Best Stocks To Trade! Click Here
To receive our complimentary newsletters please copy and paste http://www.emergingmarketsllc.com in to your web browser. On the upper right hand corner of the homepage enter your E mail address and click sign up. You will receive a confirmation E mail, click the link and your free subscription will be active.
Bankrate, Inc. was at $46.90 up $9.15 (24.23%) Bankrate, Inc. announced today it has acquired two companies in separate transactions. The first company, Memphis based, Nationwide Card Services, Inc. ("NCS") markets a comprehensive line of consumer and business credit cards via the Internet. NCS's clients include the top financial institutions and credit card issuers. The purchase price is $26.4 million in cash with an additional $7.0 million in potential earn-out based on achieving specific financial performance metrics over the next two years.
About Bankrate, Inc.
Bankrate, Inc. and its subsidiaries engage in the ownership and operation of an Internet-based consumer banking marketplace. The company's Web site, Bankrate.com aggregates information on mortgages, credit cards, automobile loans, money market accounts, certificates of deposit, checking and ATM fees, home equity loans, and online banking fees. It operates through two segments, Online Publishing, and Print Publishing and Licensing. The Online Publishing segment sells advertising, sponsorships, and hyperlinks in connection with the company's Web sites, Bankrate.com, Interest.com, FastFind.com, and Mortgage-calc.com. The Print Publishing and Licensing segment sells advertising in the mortgage guide, deposit, and CD guide rate tables; newsletter subscriptions; and licensing of research information. The company also provides financial applications and information to a network of distribution partners and through national and state publications. It reviews approximately 4,800 financial institutions in 575 markets in 50 states. Bankrate was founded in 1993 and is headquartered in North Palm Beach, Florida.
MGI PHARMA, INC. was at $40.06 up $6.61 (19.76%) Eisai Co., Ltd. ("Eisai"), a research-based human health care (hhc) company that focuses on neurology, gastrointestinal disorders, oncology and critical care, and MGI PHARMA, Inc. (NASDAQ: MOGN - News) ("MGI PHARMA"), an oncology and acute care focused biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI PHARMA for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
About MGI PHARMA, INC.
MGI PHARMA, INC., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products in the areas of oncology and acute care in the United States. Its products include Aloxi injection for the prevention of chemotherapy-induced nausea and vomiting (CINV); Dacogen for Injection, for the treatment of patients with myelodysplastic syndrome; Gliadel Wafer for the treatment of malignant glioma, and recurrent glioblastoma multiforme; Salagen Tablets, a treatment for the symptoms of xerostomia induced by radiation therapy in head and neck cancer patients; and Hexalen capsules for the treatment of ovarian cancer. The company's products in various phases of clinical trials comprise Aquavan Injection for sedation of patients undergoing diagnostic or surgical procedures; Aloxi Injection for the prevention of post operative nausea and vomiting; Aloxi Oral Capsule Formulation for the prevention of CINV; Saforis Powder for oral suspension; Amolimogene bepiplasmid to enhance the natural immune response of a patient infected with human papillomavirus; ZYC300, an encapsulated plasmid; Irofulven for chemotherapy treatment of cancer; PARP inhibitor compounds; and glutamate carboxypeptidase II for the prevention and treatment of chemotherapy-induced neuropathy. MGI PHARMA markets its products through direct sales force in the United States and through alliances with other pharmaceutical or biotechnology companies internationally. The company was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990. MGI PHARMA is headquartered in Bloomington, Minnesota.
Nuvelo, Inc. was at $2.58 up $.46 (21.69%) Nuvelo, Inc. (Nasdaq: NUVO - News) Sunday announced results from the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-2) trial (N=303), demonstrating that alfimeprase, the company's lead product candidate, actively restored catheter function and was well-tolerated in patients with catheter occlusion (CO). These data were presented yesterday in a poster session by Stephan Moll, M.D., associate professor at the University of North Carolina Medical School in Chapel Hill; Department of Medicine, Division of Hematology-Oncology, at the American Society of Hematology (ASH) 49th Annual Meeting, in Atlanta, GA. A webcast will be held Monday, December 10th at 4:30 p.m. ET to review these data.
About Nuvelo, Inc.
Nuvelo, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for acute cardiovascular and cancer therapy primarily in the United States. Its development pipeline includes three acute cardiovascular programs, such as alfimeprase, a recombinant direct-acting fibrinolytic, for the treatment of thrombotic-related disorders; rNAPc2, a recombinant nematode anticoagulant protein, which completed phase II clinical trials for acute coronary syndromes; and NU172, a thrombin inhibiting aptamer, which is in preclinical trials. The company's oncology pipeline includes rNAPc2, in phase II trials, for the treatment of metastatic colorectal cancer; NU206, a recombinant secreted protein, which completed preclinical studies for use in supportive cancer therapy, as well as for inflammatory bowel disease and short bowel syndrome; and various cancer antibodies. Nuvelo has partnership with Bayer HealthCare AG; Amgen, Inc.; Dendreon Corporation; and Archemix Corporation. The company was founded in 1991 and is headquartered in San Carlos, California.
About Emerging Markets Consulting, LLC
Emerging Markets Consulting, LLC is an investor relations and consulting firm serving carefully selected micro cap and small cap clients. Services available include turnkey investor relations services, consulting, marketing and related services needed by publicly traded companies. EMC is unique in that they only work with companies after a stringent due diligence process and they also work with a limited number of clients in order to provide service that is exceptional. The above referenced companies are not clients of Emerging Markets and no compensation has been paid for the exposure provided by this report.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
CONTACT: Emerging Markets Consulting, LLC Tel: +1 321 206 6682 e-mail: jamespainter@emergingmarketsllc.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
